Day Zero is an infectious disease diagnostic technology developer in the United States, dedicated to the development of Blood2Bac (a method for extracting bacterial DNA from clinical samples). In addition to this, the company has established a large database, Micro hmDB, which contains the whole genome sequences of pathogens and their resistance to antibiotics. Recently, Day Zero announced that it has received $8.2 million in optional phase funding from CARB-X.
This article is reproduced from: https://www.itjuzi.com/investevent/13630719
This site is for inclusion only, and the copyright belongs to the original author.